삼천당제약

000250KOSDAQ

49.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 28.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Samcheon Pharmaceutical, established in 1943, is a leading manufacturer and distributor of prescription pharmaceuticals, specializing in antibiotics, cardiovascular treatments, digestive system medications, and ophthalmic solutions. In 2024, its consolidated sales reached 231.8 billion won, a 9.9% increase from the previous year, with its subsidiary Optus Pharmaceuticals reporting a 6.4% rise in sales to 87.16 billion won.

Number of Employees

436people

Average Salary

65.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

889.38Industry Average 15.000.0Point

59.3x industry avg (risky)

PBR

12.97Industry Average 1.200.0Point

10.8x industry avg (risky)

ROE

3.37Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

25.05Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲74.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 201,000Won52-week high 1,184,00052-week low 126,500

1-month return6.0Point

1m +28.11% (strong rise)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-20
Neutral[기재정정]반기보고서 (2026.06)2026-10-08
Neutral[기재정정]분기보고서 (2026.03)2026-10-08
Neutral[기재정정]투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 캐나다 독점판매권 공급계약 체결 및 중동 6개 국가 추가 계약 체결)2026-10-01